Skip to content

Scientific publications

  • article Lapointe-Belleau A, Rouleau M, Villeneuve L, Descarreaux J, Caron P, Beaudoin C, Uchil A, Simonyan D, Dahmani C, Joly-Beauparlant C, Gélinas V, Droit A, Marcoux N, Castonguay V, Lacombe L, Lévesque É and Guillemette C

    Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer

    BMC Cancer 25 (1), 2025.

    DOI PUBMED
  • article De Vries-Brilland M, Hamilou Z, Ghosh S, Heng DYC, Wood LA, Basappa NS, Kollmannsberger CK, Graham J, Bhindi B, Finelli A, Bjarnason GA, Bosse D, Pouliot F, Castonguay V, Breau RH, Saleh RR, Winquist E, Lalani AA, Soulières D

    Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma

    Oncologist 30 (9), 2025.

    DOI PUBMED
  • article Roberge-Maltais E, Lévesque E, Castonguay V, Marcoux N, Grenier LP, Veilleux M

    Pembrolizumab-Induced Simultaneous and Refractory Systemic Capillary Leak and Cytokine Release Syndromes: A Case Report

    Curr Oncol 32 (8), 2025.

    DOI PUBMED
  • article Yap TA, Tan DSP, Stathis A, Shapiro GI, Iwasa S, Joerger M, Zhang J, Plummer R, Sawyer MB, Tan DSW, Castonguay V, Gabrail NY, Matsubara N, Wilkinson G, Ludwig M, Schlicker A, Zhou Y, Merz C, Däbritz JHM, Jeffers M, Hreiki J, de Bono JS

    Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects

    Cancer Discov 15 (10), 2025.

    DOI PUBMED
  • article Bou-Nehme Sawaya G, Tanguay S, Wood LA, Kollmannsberger C, Basappa NS, Bansal R, Soulières D, Finelli A, Heng DYC, Castonguay V, Canil C, Winquist E, Graham J, Bjarnason GA, Bhindi B, Lalani AK, Pouliot F, Breau RH, Saleh R, Dragomir A

    Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study

    Clin Genitourin Cancer 23 (3), 2025.

    DOI PUBMED
  • article Lorusso D, Colombo N, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Olivera M, Samouëlian V, Castonguay V, Arkhipov A, Li K, Toker S, Tekin C, Tewari KS, Monk BJ

    Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study

    Ann Oncol 36 (1), 2025.

    DOI PUBMED
  • article Sawaya GB, Dragomir A, Wood LA, Kollmannsberger C, Basappa NS, Kapoor A, Soulières D, Finelli A, Heng DYC, Castonguay V, Canil C, Winquist E, Graham J, Bjarnason GA, Bhindi B, Lalani AK, Pouliot F, Breau RH, Saleh R, Tanguay S

    Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

    Eur Urol Oncol 7 (3), 2024.

    DOI PUBMED
  • article Choueiri TK, Kuzel TM, Tykodi SS, Verzoni E, Kluger H, Nair S, Perets R, George S, Gurney H, Pachynski RK, Folefac E, Castonguay V, Lee CH, Vaishampayan U, Miller WH, Bhagavatheeswaran P, Wang Y, Gupta S, DeSilva H, Lee CW, Escudier B, Motzer RJ

    Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial

    ESMO Open 9 (12), 2024.

    DOI PUBMED
  • article Pouliot F, Saad F, Rousseau E, Richard PO, Zamanian A, Probst S, Lévesque É and Castonguay V, Marcoux N, Lodde M, Juneau D, Hamilou Z, Lattouf JB, Buteau FA, Pavic M, Castilloux JF, Neveu B, Bouvet GF, Allard C, Tétu A, Guérin B, Beauregard JM and

    Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study

    J Nucl Med 65 (11), 2024.

    DOI PUBMED
  • article Graham J, Ahmad AE, Basappa NS, Bernhard JC, Bhindi B, Bossé D, Breau RH, Canil CM, Castonguay V, Finelli A, Heng DYC, Inman BA, Kollmannsberger C, Lalani AA, Lavallée LT, Msaouel P, Prendeville S, Soleimani M, Tanguay S, Wood L, Richard PO

    2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma

    Can Urol Assoc J 18 (11), 2024.

    DOI PUBMED
  • article Graham J, Ghosh S, Breau RH, Wood L, Tanguay S, Bosse D, Lalani AK, Bhindi B, Heng D, Finelli A, Fallah-Rad N, Castonguay V, Basappa NS, Soulières D, Pouliot F, Kollmannsberger C, Bjarnason GA

    Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Informati…

    Clin Genitourin Cancer 22 (3), 2024.

    DOI PUBMED
  • article Park CL, Moria FA, Ghosh S, Wood L, Bjarnason GA, Bhindi B, Heng DYC, Castonguay V, Pouliot F, Kollmannsberger CK, Bosse D, Basappa NS, Finelli A, Fallah-Rad N, Breau RH, Lalani AA, Tanguay S, Graham J, Saleh RR

    Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database

    Curr Oncol 31 (8), 2024.

    DOI PUBMED